Ezetimibe Patent Expiration
Ezetimibe is Used for lowering cholesterol levels in patients with primary hyperlipidemia. It was first introduced by Organon Llc A Sub Of Organon And Co
Ezetimibe Patents
Given below is the list of patents protecting Ezetimibe, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zetia |
US7612058 (Pediatric) | Methods for inhibiting sterol absorption | Apr 30, 2026 | Organon |
| Zetia | US7612058 | Methods for inhibiting sterol absorption | Oct 30, 2025 | Organon |
| Zetia |
US7030106 (Pediatric) | Sterol absorption inhibitor compositions |
Jul 25, 2022
(Expired) | Organon |
| Zetia | US7030106 | Sterol absorption inhibitor compositions |
Jan 25, 2022
(Expired) | Organon |
| Zetia |
USRE37721 (Pediatric) | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr 25, 2017
(Expired) | Organon |
| Zetia |
USRE42461 (Pediatric) | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr 25, 2017
(Expired) | Organon |
| Zetia | USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct 25, 2016
(Expired) | Organon |
| Zetia | USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct 25, 2016
(Expired) | Organon |
| Zetia |
US5846966 (Pediatric) | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar 21, 2014
(Expired) | Organon |
| Zetia | US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep 21, 2013
(Expired) | Organon |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Ezetimibe's patents.
Latest Legal Activities on Ezetimibe's Patents
Given below is the list recent legal activities going on the following patents of Ezetimibe.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Correspondence Address Change Critical
| 10 Aug, 2021 | US7030106 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Apr, 2021 | US7612058 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Sep, 2017 | US7030106 |
| Post Issue Communication - Certificate of Correction | 08 Jan, 2014 | US7612058 |
| Mail-Petition Decision - Granted | 21 Oct, 2013 | US7612058 |
| Adjustment of PTA Calculation by PTO | 21 Oct, 2013 | US7612058 |
| Petition Decision - Granted Critical
| 21 Oct, 2013 | US7612058 |
| Correspondence Address Change Critical
| 26 Aug, 2011 | US7030106 |
| Appellant's Complaint | 30 Apr, 2010 | US7612058 |
| Petition Entered | 22 Dec, 2009 | US7612058 |
Ezetimibe's Family Patents
